Issue 3, 2018

Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors

Abstract

Herein we describe the design, synthesis, and biological evaluation of a novel series of tranylcypromine-based LSD1 inhibitors via conformational restriction using spiro ring systems. A simple, direct spirocyclic analog of tranylcypromine (compounds 8a and 8b) was shown to be a 28- to 129-fold more potent inhibitor of LSD1 enzyme compared to tranylcypromine. Further incorporation of various substituted benzyl groups to the amino group resulted in a suite of 2′,3′-dihydrospiro[cyclopropane-1,1′-inden]-2-amines that are potent LSD1 inhibitors with excellent selectivity profiles (e.g.14a, 15b, 16a, 19a and 20b) against closely related enzymes such as MAO-A, MAO-B, and LSD2.

Graphical abstract: Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors

Supplementary files

Article information

Article type
Paper
Submitted
06 Dec 2017
Accepted
21 Dec 2017
First published
05 Jan 2018
This article is Open Access
Creative Commons BY license

RSC Adv., 2018,8, 1666-1676

Novel spirocyclic tranylcypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors

Y. Shi, Y. Wu, M. Su, D. Shen, H. Gunosewoyo, F. Yang, J. Li, J. Tang, Y. Zhou and L. Yu, RSC Adv., 2018, 8, 1666 DOI: 10.1039/C7RA13097J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements